Next Investors (06/06/24 note) claims 3x better RSBQ score than Neuren's.
This is probably cherry picking the data because the caregivers assessment will always be less objective than the clinicians - but to be discussed in the arena as (FDA approved) trofinetide is positive.
The NI Note is a good read and Duthy's investor presso also insightful.
